1
|
Wang L, Cai C, Huang L, Shi D, Chen Q, Chen Y, Yu W. Safety profile of methotrexate used off-label in ectopic pregnancy: an active monitoring study based on a Chinese hospital pharmacovigilance system. Curr Med Res Opin 2024; 40:35-42. [PMID: 37975718 DOI: 10.1080/03007995.2023.2285375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Accepted: 11/15/2023] [Indexed: 11/19/2023]
Abstract
OBJECTIVE Methotrexate (MTX) is characterized as first-line therapy although its indication of ectopic pregnancy is off-label use. We aimed to conduct a retrospective cohort study to investigate the incidence, characteristics of adverse drug reactions (ADRs) of MTX, provide valuable insights for medical workers. METHODS Basing on China Hospital Pharmacovigilance System (CHPS), a retrospective analysis was performed to evaluate the safety of MTX (n = 672). An active monitoring model was set to detect ADR signals from the hospital information system. Frequency, Common Terminology Criteria for Adverse Events (CTCAE) grade proportion and association of dose exposure with ADRs were presented as outcomes. RESULTS The total incidence of ADRs was 54.0%. Anaemia (37.6%) was the most frequent ADR, followed by hepatic function abnormal (11.3%), hyperuricemia (6.1%), neutropenia (4.6%), leukopenia (4.0%), and dyslipidaemia (2.5%). For the composition of all ADRs, CTCAE grade one, two and three dominated for 86.3%, 12.1% and 1.6%, respectively. The severity of hepatic function abnormal was more serious in the two-dose exposed group (p = .021), while other types of ADRs had no statistical or clinical differences. Logistic regression analysis showed the incidence of any ADRs (OR 1.87 [1.31-2.64]; p = .001), hepatic function abnormal (OR 2.75 [1.69-4.48]; p < .001), dyslipidaemia (OR 5.15 [1.87-14.13]; p = .001) were significantly higher in the two-dose exposed group. After adjusted, the positive associations were still maintained. CONCLUSIONS MTX is quite safe in ectopic pregnancy, despite its mild to moderate hematotoxicity, hepatotoxicity and nephrotoxicity. Taking CHPS can present the accurate denominator of the incidence of adverse drug reactions into account, our study advocates that it may have great potential to be used as an active monitoring tool for off-label drug use risk management.
Collapse
Affiliation(s)
- Lingsong Wang
- Scientific Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| | - Can Cai
- Scientific Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| | - Lurong Huang
- Department of Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| | - Danni Shi
- Scientific Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| | - Quanyao Chen
- Scientific Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| | - Yao Chen
- Scientific Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| | - Weiwei Yu
- Department of Obstetrics, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China
| |
Collapse
|
2
|
das Neves J, Notario-Pérez F, Sarmento B. Women-specific routes of administration for drugs: A critical overview. Adv Drug Deliv Rev 2021; 176:113865. [PMID: 34280514 DOI: 10.1016/j.addr.2021.113865] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 07/07/2021] [Accepted: 07/09/2021] [Indexed: 12/19/2022]
Abstract
The woman's body presents a number of unique anatomical features that can constitute valuable routes for the administration of drugs, either for local or systemic action. These are associated with genitalia (vaginal, endocervical, intrauterine, intrafallopian and intraovarian routes), changes occurring during pregnancy (extra-amniotic, intra-amniotic and intraplacental routes) and the female breast (breast intraductal route). While the vaginal administration of drug products is common, other routes have limited clinical application and are fairly unknown even for scientists involved in drug delivery science. Understanding the possibilities and limitations of women-specific routes is of key importance for the development of new preventative, diagnostic and therapeutic strategies that will ultimately contribute to the advancement of women's health. This article provides an overview on women-specific routes for the administration of drugs, focusing on aspects such as biological features pertaining to drug delivery, relevance in current clinical practice, available drug dosage forms/delivery systems and administration techniques, as well as recent trends in the field.
Collapse
|
3
|
Dolinko AV, Vrees RA, Frishman GN. Non-tubal Ectopic Pregnancies: Overview and Treatment via Local Injection. J Minim Invasive Gynecol 2018; 25:287-296. [DOI: 10.1016/j.jmig.2017.07.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 07/10/2017] [Accepted: 07/13/2017] [Indexed: 12/11/2022]
|
4
|
Bonin L, Pedreiro C, Moret S, Chene G, Gaucherand P, Lamblin G. Predictive factors for the methotrexate treatment outcome in ectopic pregnancy: A comparative study of 400 cases. Eur J Obstet Gynecol Reprod Biol 2016; 208:23-30. [PMID: 27888702 DOI: 10.1016/j.ejogrb.2016.11.016] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Revised: 10/08/2016] [Accepted: 11/15/2016] [Indexed: 11/24/2022]
Abstract
OBJECTIVE We sought to evaluate the global success rate of intramuscular methotrexate for the treatment of ectopic pregnancy, identify factors predictive of treatment success or failure, and study methotrexate tolerability in a large patient cohort. STUDY DESIGN For this single-center retrospective observational study, we retrieved the records of all women who had a clinically or echographically confirmed ectopic pregnancy with a Fernandez score <13 and who were treated according to a 1mg/kg intramuscular single-dose methotrexate protocol. Medical treatment failure was defined by an obligation to proceed to laparoscopy. Needing a second injection was not considered to be medical treatment failure. RESULTS Between February 2008 and November 2013 (69 months), 400 women received methotrexate for ectopic pregnancy. The medical treatment protocol was effective for 314 patients, i.e., an overall success rate of 78.5%. A single methotrexate dose was sufficient for 63.5% of the women and a second dose was successful for 73.2% of the remaining women. The medical treatment success rate fell as initial hCG levels climbed. The main factors associated with methotrexate failure included day (D) 0, D4 and D7 hCG levels, pretherapeutic blood progesterone, hematosalpinx at D0 and pain at D7. Early favorable kinetics of hCG levels was predictive of success. Methotrexate treatment was successful in 90% of women who had D0 hCG <1000IU/l. Methotrexate tolerability was good, with only 9% of the women reporting non-severe adverse effects. The fertility rate with delivery after medical treatment for ectopic pregnancy was 80.7%. CONCLUSION In this study, we showed that an initial hCG value <1000IU/l and favorable early HCG kinetics were predictive factors for the successful medical treatment of ectopic pregnancy by methotrexate, and hematosalpinx and pretherapeutic blood progesterone >5ng/ml at diagnosis were predictive of its failure. We also confirmed good tolerability for single-dose methotrexate protocols.
Collapse
Affiliation(s)
- Lucie Bonin
- Department of Obstetrics and Gynecology Surgery, Femme Mère Enfant Hospital, Lyon, Hospices Civils de Lyon, France
| | - Cécile Pedreiro
- Department of Obstetrics and Gynecology Surgery, Femme Mère Enfant Hospital, Lyon, Hospices Civils de Lyon, France
| | - Stéphanie Moret
- Clinical Research Associate, Hospices Civils de Lyon, Femme Mère Enfant University Hospital, Department of Obstetrics and Gynecology, Lyon, France
| | - Gautier Chene
- Department of Obstetrics and Gynecology Surgery, Femme Mère Enfant Hospital, Lyon, Hospices Civils de Lyon, France
| | - Pascal Gaucherand
- Department of Obstetrics and Gynecology Surgery, Femme Mère Enfant Hospital, Lyon, Hospices Civils de Lyon, France
| | - Géry Lamblin
- Department of Obstetrics and Gynecology Surgery, Femme Mère Enfant Hospital, Lyon, Hospices Civils de Lyon, France.
| |
Collapse
|
5
|
Overview and guidelines of off-label use of methotrexate in ectopic pregnancy: report by CNGOF. Eur J Obstet Gynecol Reprod Biol 2016; 205:105-9. [DOI: 10.1016/j.ejogrb.2016.07.489] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Revised: 07/01/2016] [Accepted: 07/25/2016] [Indexed: 12/27/2022]
|
6
|
États des lieux et expertise de l’usage hors AMM du méthotrexate en gynécologie–obstétrique : travail du CNGOF. ACTA ACUST UNITED AC 2015; 44:230-6. [DOI: 10.1016/j.jgyn.2014.12.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 12/01/2014] [Indexed: 12/27/2022]
|
7
|
Misme H, Agostini A, Dubernard G, Tourette C. [Indications for methotrexate in gynecology outside the first-line treatment of ectopic tubal pregnancies]. J Gynecol Obstet Hum Reprod 2015; 44:220-229. [PMID: 25666162 DOI: 10.1016/j.jgyn.2014.12.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 12/02/2014] [Indexed: 06/04/2023]
Abstract
The objective of this work is to discuss the indications for methotrexate in gynecology outside the first-line treatment of tubal ectopic pregnancy. In tubal ectopic pregnancy, the prophylactic use of systemic methotrexate can be discussed when performing laparoscopic salpingotomy. In case of failure of salpingotomy, administration seems justified especially if it avoids re-intervention. The combination of methotrexate with other therapies such as mifepristone, potassium chloride or gefitinib is not recommended in the treatment of ectopic pregnancy. For non-tubal ectopic pregnancy, the intramuscular or local administration of methotrexate is an acceptable treatment for uncomplicated interstitial pregnancies. For uncomplicated cervical or cesarean scar pregnancies, the local administration of methotrexate should be considered as a first-line treatment. For ovarian pregnancies, methotrexate should not be a first-line treatment, surgical treatment remains the standard. Asymptomatic women presenting with a pregnancy of unknown location and plateauing serum hCG concentration<2000 UI/L can be managed expectantly: it is recommended to take an additional quantitative hCG serum level after 48 hours. Thus, methotrexate is not recommended in the first intention. Other gynecological indications were discussed: methotrexate is not recommended in the management of first-trimester miscarriages or in the management of placenta accreta.
Collapse
Affiliation(s)
- H Misme
- Service de gynécologie-obstétrique de l'hôpital de la Croix-Rousse, hospices civils de Lyon, 103, Grand rue de la Croix-rousse, 69004 Lyon, France.
| | - A Agostini
- Service de gynécologie-obstétrique, CHU de La Conception, 147, boulevard Baille, 13385 Marseille cedex 05, France
| | - G Dubernard
- Service de gynécologie-obstétrique de l'hôpital de la Croix-Rousse, hospices civils de Lyon, 103, Grand rue de la Croix-rousse, 69004 Lyon, France
| | - C Tourette
- Service de gynécologie-obstétrique, CHU de La Conception, 147, boulevard Baille, 13385 Marseille cedex 05, France.
| |
Collapse
|
8
|
Lesavre M, Curinier S, Capmas P, Rabischong B, Fernandez H. [Treatment of tubal ectopic pregnancy by methotrexate]. ACTA ACUST UNITED AC 2015; 44:212-9. [PMID: 25661494 DOI: 10.1016/j.jgyn.2014.12.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Accepted: 12/02/2014] [Indexed: 11/15/2022]
Abstract
OBJECTIVES To make a literature analyse about methotrexate as a treatment of tubal ectopic pregnancy. MATERIALS AND METHODS We made a PubMed research and found articles, randomized control studies, systematic revues and meta-analyses of the Cochrane Database about ectopic pregnancies treated by methotrexate. We made a summary of these articles. RESULTS Methotrexate can be used as a treatment of tubal ectopic pregnancy with hCG<5000 UI/L and expectative is an option if hCG level is lower than 1500 UI/L. Medical treatment by methotrexate seems to be less effective than surgical salpingotomy but the rate of recurrence and the rate of intra-uterine pregnancy are similar regardless of the treatment chosen. Fertility seems to be the same after treatment by methotrexate. Economically, methotrexate is less expensive than the surgical management (laparoscopy). CONCLUSION Methotrexate can be used as a treatment of tubal ectopic pregnancies if every criterions of safety are gathered.
Collapse
Affiliation(s)
- M Lesavre
- Service de gynécologie-obstétrique, CHU Bicêtre, 78, avenue du général-Leclerc, 94276 Le Kremlin-Bicêtre, France.
| | - S Curinier
- Service de gynécologie-obstétrique, CHU Estaing, 1, place Lucie-Aubrac, 63003 Clermont Ferrand, France
| | - P Capmas
- Service de gynécologie-obstétrique, CHU Bicêtre, 78, avenue du général-Leclerc, 94276 Le Kremlin-Bicêtre, France
| | - B Rabischong
- Service de gynécologie-obstétrique, CHU Estaing, 1, place Lucie-Aubrac, 63003 Clermont Ferrand, France
| | - H Fernandez
- Service de gynécologie-obstétrique, CHU Bicêtre, 78, avenue du général-Leclerc, 94276 Le Kremlin-Bicêtre, France
| |
Collapse
|
9
|
Shaaban OM, Othman AS, Elkarim AA, Ali MK. Spontaneous Second Trimester Heterotopic Pregnancy. J Gynecol Surg 2014. [DOI: 10.1089/gyn.2013.0097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Omar M. Shaaban
- Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt
| | - Alaa S. Othman
- Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt
| | | | | |
Collapse
|
10
|
Dai Q, Wang LL, Shao XH, Wang SM, Dong XQ. Clinical effectiveness of multiple-drug injection treatment in unruptured ectopic pregnancies: a retrospective study. JOURNAL OF ULTRASOUND IN MEDICINE : OFFICIAL JOURNAL OF THE AMERICAN INSTITUTE OF ULTRASOUND IN MEDICINE 2012; 31:1627-1634. [PMID: 23011626 DOI: 10.7863/jum.2012.31.10.1627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
OBJECTIVES To study the effect of local interventional treatment of unruptured ectopic pregnancies with multiple-drug injection guided by color Doppler sonography. METHODS In this retrospective analysis, 49 patients with an unruptured ectopic pregnancy were treated with two different local injection methods administered under sonographic guidance. The patients were divided into single-drug (n = 23) and multiple-drug (n = 26) injection groups, and they received a locally administered injection of methotrexate alone or a combination including methotrexate, hemocoagulase, antibiotics, and anti-inflammatory drugs, respectively. Overall, local injection treatment was successful in 44 patients. The 5 patients with failed treatment underwent laparotomy about 1 week after single-drug injection. Serum β-human chorionic gonadotropin (β-hCG ) levels, ectopic pregnancy mass sizes, blood flow at various points after treatment, the incidence of pelvic bleeding, and the time for serum β-hCG levels to return to normal and the mass to resolve were analyzed in the remaining 44 patients. RESULTS Single-drug treatment was successful in 18 patients; 10 of 23 had low to moderate pelvic bleeding after treatment, and 5 were referred for surgery. All 26 patients were successfully treated by multiple-drug injection. Only 2 patients had a small amount of pelvic bleeding. Differences between groups were statistically significant (P < .05) for surgery rates, the incidence of pelvic bleeding, transient increases in serum β-hCG levels, mean days to normal β-hCG levels, mean days of mass resolution, and mean mass diameters 1 to 6 weeks after treatment. CONCLUSIONS Local multiple-drug injection under color Doppler guidance is a new, safe, and effective method for treating unruptured ectopic pregnancies. It accelerates the serum β-hCG decline and facilitates mass resolution. This regimen is associated with a very low rate of pelvic bleeding, improves the success rate of conservative treatment, and, therefore, has value as an important clinical application.
Collapse
Affiliation(s)
- Quan Dai
- Department of Ultrasonography, Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan St, 150001 Harbin, Heilongjiang Province, China
| | | | | | | | | |
Collapse
|
11
|
Moores KL, Keriakos RH, Anumba DO, Connor ME, Lashen H. Management challenges of a live 12-week sub-hepatic intra-abdominal pregnancy. BJOG 2009; 117:365-8. [PMID: 20015307 DOI: 10.1111/j.1471-0528.2009.02450.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- K L Moores
- ST5 in Obstetrics and Gynaecology, Doncaster Women's Hospital, Doncaster, UK.
| | | | | | | | | |
Collapse
|
12
|
Abstract
There has been an increase in the incidence of ectopic pregnancy to epidemic proportions in many developed countries in the past two decades. In 1989, ectopic pregnancy accounted for 1.6% of all pregnancies in the United States of America. This trend may be explained by an increase in the incidence of established risk factors as well as a dramatic improvement in diagnostic tools and advances in reproductive technology. Technologic advances such as highly sensitive radioimmunoassays for the β-subunit of human chorionic gonadotropin (βhCG), the development of high-resolution ultrasound and a heightened physician awareness have revolutionized the clinical management of ectopic pregnancy, leading to earlier and more consistent diagnoses and consequently reduced maternal mortality rates. 1,3–13 Unfortunately, ectopic pregnancy is still associated with a significant morbidity and mortality and contributes substantially to health-care costs. For example ectopic pregnancy complications accounted for 13% of all pregnancy-related deaths and were the leading cause of maternal mortality in African- American women in 1989. Financially, an estimated 1.1 billion dollars was spent in the United States of America alone for the management of ectopic pregnancy in 1990.
Collapse
|
13
|
Conservative management of tubal ectopic pregnancy. Best Pract Res Clin Obstet Gynaecol 2009; 23:509-18. [PMID: 19299204 DOI: 10.1016/j.bpobgyn.2008.12.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2008] [Accepted: 12/15/2008] [Indexed: 11/22/2022]
Abstract
In this chapter an overview is given of the best available evidence on the conservative treatment for tubal ectopic pregnancy, i.e., expectant management and medical treatment with systemic methotrexate. From the two randomized controlled trials on expectant management, no conclusions can be drawn yet. It may be that women with low serum hCG levels need not be treated at all, but more research needs to be done in this subgroup of women to reach firm conclusions. Systemic methotrexate in a fixed multiple-dose i/m regimen can be recommended for hemodynamically stable women with an unruptured tubal ectopic pregnancy and no signs of active bleeding presenting with serum hCG concentrations<3,000 IU/l. In women with serum hCG concentrations<1,500 IU/l, a single-dose methotrexate regimen can be considered.
Collapse
|
14
|
Cipullo L, Cassese S, Fasolino L, Fasolino MC, Fasolino A. Cervical pregnancy: a case series and a review of current clinical practice. EUR J CONTRACEP REPR 2009; 13:313-9. [PMID: 18821465 DOI: 10.1080/13625180802254571] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Five consecutive cases of cervical pregnancy (CP) are presented. In four cases, the diagnosis was made at routine check-ups and these were all treated conservatively. In the fifth case, an erroneous diagnosis of inevitable abortion was made, in a patient presenting with profuse vaginal bleeding. Persistent bleeding following curettage required an emergency hysterectomy, after failure of compressive methods. From the four cases treated conservatively, three received standard methotrexate i.m. (MTX) in combination with bilateral uterine artery embolization (UAE). In one case MTX was followed by intraamniotic puncture and instillation of KCl due to persistent embryonic heartbeat. A spontaneous evacuation of the cervical pregnancy occurred in all patients treated conservatively. We postulate that the preventive use of uterine artery embolization in combination with standard MTX treatment could contribute to reduce the risk of excessive bleeding and facilitate spontaneous expulsion. Possible detrimental effects of the treatment on subsequent reproductive capacities and obstetrical outcome are also pointed out. The diagnostic methods and therapeutic approaches are discussed and the literature is reviewed. With referral to the first case of our series, which required an emergency hysterectomy, we want to stress the importance of an early diagnosis for a correct management of this condition.
Collapse
Affiliation(s)
- Lucio Cipullo
- Department of Obstetrics and Gynaecology, General Hospital S. Giovanni di Dio e Ruggi d'Aragona-Salerno, Italy.
| | | | | | | | | |
Collapse
|
15
|
Tubal ectopic pregnancy: diagnosis and management. Arch Gynecol Obstet 2008; 279:443-53. [DOI: 10.1007/s00404-008-0731-3] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2008] [Accepted: 07/08/2008] [Indexed: 12/27/2022]
|
16
|
Hajenius PJ, Mol F, Mol BWJ, Bossuyt PMM, Ankum WM, van der Veen F. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007; 2007:CD000324. [PMID: 17253448 PMCID: PMC7043290 DOI: 10.1002/14651858.cd000324.pub2] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Treatment options for tubal ectopic pregnancy are; (1) surgery, e.g. salpingectomy or salpingo(s)tomy, either performed laparoscopically or by open surgery; (2) medical treatment, with a variety of drugs, that can be administered systemically and/or locally by various routes and (3) expectant management. OBJECTIVES To evaluate the effectiveness and safety of surgery, medical treatment and expectant management of tubal ectopic pregnancy in view of primary treatment success, tubal preservation and future fertility. SEARCH STRATEGY The Cochrane Menstrual Disorders and Subfertility Group's Specialised Register, Cochrane Controlled Trials Register (up to February 2006), Current Controlled Trials Register (up to October 2006), and MEDLINE (up to October 2006) were searched. SELECTION CRITERIA Randomised controlled trials (RCTs) comparing treatments in women with tubal ectopic pregnancy. DATA COLLECTION AND ANALYSIS Data extraction and quality assessment was done independently by two reviewers. Differences were resolved by discussion with all reviewers. MAIN RESULTS Thirty five studies have been analysed on the treatment of tubal ectopic pregnancy, describing 25 different comparisons. SURGERY Laparoscopic salpingostomy is significantly less successful than the open surgical approach in the elimination of tubal ectopic pregnancy (2 RCTs, n=165, OR 0.28, 95% CI 0.09, 0.86) due to a significant higher persistent trophoblast rate in laparoscopic surgery (OR 3.5, 95% CI 1.1, 11). However, the laparoscopic approach is significantly less costly than open surgery (p=0.03). Long term follow-up (n=127) shows no evidence of a difference in intra uterine pregnancy rate (OR 1.2, 95% CI 0.59, 2.5) but there is a non significant tendency to a lower repeat ectopic pregnancy rate (OR 0.47, 95% 0.15, 1.5). Salpingostomy alone is significantly less successful than when combined with a prophylactic single shot methotrexate (2 RCTs, n=163, OR 0.25, 95% CI 0.08-0.76) to prevent persistent trophoblast. MEDICAL TREATMENT Systemic methotrexate in a fixed multiple dose intramuscular regimen has a non significant tendency to a higher treatment success than laparoscopic salpingostomy (1 RCT, n=100, OR 1.8, 95% CI 0.73, 4.6). No significant differences are found in long term follow-up (n=74): intra uterine pregnancy (OR 0.82, 95% CI 0.32, 2.1) and repeat ectopic pregnancy (OR 0.87, 95% CI 0.19, 4.1). One single dose intramuscular methotrexate is significantly less successful than laparoscopic salpingostomy (4 RCTs, n=265, OR 0.38, 95% CI 0.20, 0.71). With a variable dose regimen treatment success rises, but shows no evidence of a difference compared to laparoscopic salpingostomy (OR 1.1, 95% CI 0.52, 2.3). Long term follow-up (n=98) do not differ significantly (intra uterine pregnancy OR 1.0, 95% CI 0.43, 2.4, ectopic pregnancy OR 0.54, 95% CI 0.12, 2.4). The efficacy of systemic single dose methotrexate alone is significantly less successful than when combined with mifepristone (2 RCTs, n=262, OR 0.59, 95% CI 0.35, 1.0). The same goes for the addition of traditional Chinese medicine (1 RCT, n=78, OR 0.08, 95% CI 0.02, 0.39). Local medical treatment administered transvaginally under ultrasound guidance is significantly better than a 'blind' intra-tubal injection under laparoscopic guidance in the elimination of tubal ectopic pregnancy (1 RCT, n=36, methotrexate OR 5.8, 95% CI 1.3, 26; 1 RCT, n=80, hyperosmolar glucose OR 0.38, 95% CI 0.15, 0.93). However, compared to laparoscopic salpingostomy, local injection of methotrexate administered transvaginally under ultrasound guidance is significantly less successful (1 RCT, n=78, OR 0.17, 95% CI 0.04, 0.76) but with positive long term follow up (n=51): a significantly higher intra uterine pregnancy rate (OR 4.1, 95% CI 1.3, 14) and a non significant tendency to a lower repeat ectopic pregnancy rate (OR 0.30, 95% CI 0.05, 1.7). EXPECTANT MANAGEMENT: Expectant management is significantly less successful than prostaglandin therapy (1 RCT, n=23, OR 0.08, 95% CI 0.02-0.39). AUTHORS' CONCLUSIONS In the surgical treatment of tubal ectopic pregnancy laparoscopic surgery is a cost effective treatment. An alternative nonsurgical treatment option in selected patients is medical treatment with systemic methotrexate. Expectant management can not be adequately evaluated yet.
Collapse
Affiliation(s)
- P J Hajenius
- Academic Medical Center, University of Amsterdam, Obstetrics and Gynecology (H4-205), Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
| | | | | | | | | | | |
Collapse
|
17
|
Abstract
Physicians not used to caring for pregnant patients may feel uncomfortable dealing with the many routine problems that can occur during a pregnancy. Other than true obstetric emergencies, which are usually cared for by obstetricians and family physicians, and the common problems of pregnancy can often be cared for by any primary care physician. Given the litigious nature of our society, especially in the realm of obstetrics, it does behoove the physician caring for pregnant women to be aware of the standards of care. When in doubt, it would be prudent to consult with a physician that routinely provides care to pregnant women.
Collapse
Affiliation(s)
- Kevin S Ferentz
- Department of Family Medicine, University of Maryland School of Medicine, 29 South Paca Street, Baltimore, MD 21201, USA
| | | |
Collapse
|
18
|
Abstract
The management of gynaecological emergencies is directed at the preservation of life, health, sexual function and the perpetuation of fertility. Ectopic pregnancy (EP), pelvic inflammatory disease (PID) and miscarriages are common gynaecological emergencies and early recognition and appropriate treatment is essential to avoid unwanted sequelae. Controversy will always exist in clinical medicine because management is mainly based on uncontrolled studies, expert opinion and personal experiences. It is estimated that only 10% of clinical treatments have been validated by prospective, randomised trials. Recent advances have led to earlier diagnosis and more conservative treatment on an outpatient or day care basis in EP and miscarriages.
Collapse
Affiliation(s)
- S R Ramphal
- Department of Obstetrics and Gynaecology, Nelson R Mandela School of Medicine, Private Bag 7, Congella 4013, South Africa.
| | | |
Collapse
|
19
|
Flo K, Bremnes RM, Maltau JM. Laparoscopic methotrexate treatment of ectopic pregnancy: feasibility, efficacy, safety and intrauterine pregnancy rates. J OBSTET GYNAECOL 2004; 20:292-6. [PMID: 15512556 DOI: 10.1080/01443610050009656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
We set out to investigate efficacy, methotrexate (MTX) plasma concentrations, and toxicity following a single injection of MTX into the gestational site in the treatment of ectopic pregnancy. This was a non-randomised, non-blinded prospective clinical trial. Eighteen women with unruptured tubal pregnancies and in stable haemodynamic condition were studied. MTX 1 mg/kg was injected into the ectopic pregnancy guided by laparoscopy. Serum betahCG levels were estimated before MTX treatment and on days 1, 4 and 13. In 14 patients plasma MTX was determined 1 h and 6 h after the injection. We found an adequate decline in betahCG was achieved in 17 (94%) patients, and tubal surgery avoided in 15 (83%). At 6 hours following drug administration, mean plasma MTX concentration (0.36+/-0.21 microM) was only 12% of mean peak level (3.1+/-1.0 microM). Six (39%) demonstrated slightly elevated, but completely reversible liver enzymes. None reported any subjective adverse effects. At the 4-7 year follow-up nine of 12 (75%) women had delivered healthy babies. It is concluded that intratubal injection of 1 mg/kg MTX appears to be an effective and safe treatment of ectopic pregnancy.
Collapse
Affiliation(s)
- K Flo
- Department of Obstetrics and Gynaecology, Tromsø University Hospital, Norway.
| | | | | |
Collapse
|
20
|
Abstract
Early pregnancy complications include miscarriage, ectopic pregnancies, pregnancies of unknown location, adnexal masses and hydatidiform mole. The management of women with these complications has changed with the introduction of dedicated Early Pregnancy Units, with a shift away from a surgical approach to one based on an expectant or 'watch and wait' policy. This chapter describes the role of transvaginal sonography (TVS) in the management of these women and critically evaluates the different treatment modalities available for the management of these complications. The management of miscarriage has largely changed from a surgical to an expectant or medical approach. The treatment of ectopic pregnancy (EP) is also being managed in a similar way as the condition is increasingly detected earlier. We will argue that EP should not be diagnosed on the basis of the absence of an intrauterine pregnancy but rather by the positive visualization of an adnexal mass using TVS. If a pregnancy cannot be seen either inside or outside the uterus this should be described as a pregnancy of unknown location and managed expectantly until the outcome is confirmed.
Collapse
Affiliation(s)
- George Condous
- Early Pregnancy, Gynaecological Ultrasound and Minimal Access Surgery Unit, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, England, UK.
| |
Collapse
|
21
|
Savary D, Fernandez H, Canis M. [Unruptured ectopic pregnancy: which therapeutic options?]. ACTA ACUST UNITED AC 2004; 129:232-6. [PMID: 15191850 DOI: 10.1016/j.anchir.2004.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2004] [Indexed: 11/22/2022]
Affiliation(s)
- D Savary
- Service de gynécologie et obstétrique, CHU de Clermont-Ferrand, polyclinique Hôtel-Dieu, boulevard Léon-Malfreyt, 63058 Clermont-Ferrand 1, France
| | | | | |
Collapse
|
22
|
|
23
|
Condous G, Okaro E, Bourne T. The conservative management of early pregnancy complications: a review of the literature. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2003; 22:420-430. [PMID: 14528481 DOI: 10.1002/uog.236] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Early pregnancy complications include miscarriage, ectopic pregnancies, adnexal masses and pregnancies of unknown location. In this review, we evaluate the role of conservative management in these complications. We also evaluate the role of transvaginal sonography for diagnosis, treatment and follow up. When managing women with early pregnancy complications, it is important to recognise the normal sonographic milestones in the first trimester. Understanding the pattern of serum human chorionic gonadotropin change in early normal pregnancy and the correlation between low serum progesterone levels and the spontaneous resolution of a pregnancy are also important concepts. Guidelines for assessing suitability for conservative management should be strictly governed by evidence based protocols. Women can then be offered expectant or medical treatment as appropriate.
Collapse
Affiliation(s)
- G Condous
- Early Pregnancy, Gynaecological Ultrasound and Minimal Access Surgery Unit, St George's Hospital Medical School, London, UK.
| | | | | |
Collapse
|
24
|
|
25
|
|
26
|
Nazac A, Gervaise A, Bouyer J, de Tayrac R, Capella-Allouc S, Fernandez H. Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2003; 21:181-185. [PMID: 12601843 DOI: 10.1002/uog.9] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
OBJECTIVE The use of methotrexate (MTX) for the treatment of tubal ectopic pregnancy (EP) has become common practice, although the factors associated with a favorable outcome are not totally clear. The aim of this study was to investigate the predictors of successful MTX treatment. METHODS One hundred and thirty-seven women with unruptured tubal EP in whom the hematosalpinx could be directly visualized by pelvic ultrasound were studied. Women who met the inclusion criteria were treated with MTX either: 50 mg/m(2) intramuscularly (n = 70) or with 1 mg/kg injected directly into the hematosalpinx under sonographic guidance (n = 67). The associations between the outcome of the treatment and different factors studied (human chorionic gonadotropin (hCG) level, progesterone level, hematosalpinx diameter, hemoperitoneum volume and mode of MTX administration) were analyzed. RESULTS The overall success rate, defined by a post-treatment normal hCG level (< 10 mIU/mL), was 79.6%. The initial hCG level and the route of administration of MTX appeared to be two independent factors that predicted success. Multivariate analysis demonstrated that the success rate was significantly better when MTX was administered locally: the odds ratio (OR) was 9.7 (95% CI, 3.1-30), and was significantly poorer when the hCG level was >/= 1000 mIU/mL (P < 0.002): the OR was 0.10 (95% CI, 0.07-0.49). CONCLUSION Among selected women with tubal EPs, the route of administration of MTX and the initial level of serum hCG are the most important factors associated with the success of medical treatment.
Collapse
Affiliation(s)
- A Nazac
- Service de Gynécologie-Obstétrique, Université Paris-Sud, Hôpital Antoine Béclère (AP-HP), Clamart cedex, France
| | | | | | | | | | | |
Collapse
|
27
|
Clinical policy: critical issues in the initial evaluation and management of patients presenting to the emergency department in early pregnancy. Ann Emerg Med 2003; 41:123-33. [PMID: 12514693 DOI: 10.1067/mem.2003.13] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
MESH Headings
- Abdominal Injuries/diagnosis
- Abdominal Injuries/therapy
- Abortifacient Agents, Nonsteroidal/administration & dosage
- Abortifacient Agents, Nonsteroidal/adverse effects
- Abortion, Spontaneous/diagnosis
- Abortion, Spontaneous/therapy
- Abortion, Threatened/diagnosis
- Abortion, Threatened/therapy
- Chorionic Gonadotropin/blood
- Diagnosis, Differential
- Emergency Service, Hospital
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin D
- Methotrexate/administration & dosage
- Methotrexate/adverse effects
- Pregnancy
- Pregnancy Complications/diagnosis
- Pregnancy Complications/therapy
- Pregnancy, Ectopic/blood
- Pregnancy, Ectopic/diagnosis
- Pregnancy, Ectopic/diagnostic imaging
- Retrospective Studies
- Rh-Hr Blood-Group System
- Time Factors
- Ultrasonography
Collapse
|
28
|
|
29
|
|
30
|
Debby A, Golan A, Sadan O, Zakut H, Glezerman M. Fertility outcome following combined methotrexate treatment of unruptured extrauterine pregnancy. BJOG 2000; 107:626-30. [PMID: 10826577 DOI: 10.1111/j.1471-0528.2000.tb13304.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To assess the effectiveness of systemic treatment with methotrexate in combination with local injection for unruptured tubal pregnancy, and to evaluate reproductive function following treatment. DESIGN Prospective, open clinical study. SETTING University clinic. POPULATION Sixty-seven women with unruptured tubal pregnancy. METHODS Systemic methotrexate (intramuscular methotrexate 0.5 mg/kg for up to five days) in combination with local application of 12.5 mg methotrexate via laparoscopy. MAIN OUTCOME MEASURES The subsequent surgical intervention required and future fertility. RESULTS In 89.6% of women no further surgical intervention was required and 47 women (81%) experienced subsequently an intrauterine pregnancy. In 39 of 40 women who underwent hysterosalpingography following treatment, patency of the affected tube was observed. CONCLUSIONS Combined local and systemic methotrexate treatment for unruptured tubal pregnancy seems to be more effective than each therapeutic modality alone.
Collapse
Affiliation(s)
- A Debby
- Department of Obstetrics and Gynaecology, The Edith Wolfson Medical Center, Holon and Sackler Medical School, Tel Aviv, Israel
| | | | | | | | | |
Collapse
|
31
|
Hajenius PJ, Mol BW, Bossuyt PM, Ankum WM, Van Der Veen F. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2000:CD000324. [PMID: 10796710 DOI: 10.1002/14651858.cd000324] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND The diagnosis of ectopic pregnancy can now often be made by non-invasive methods due to sensitive pregnancy tests (in urine and serum) and high resolution transvaginal sonography, which have been integrated in diagnostic algorithms. These algorithms, in combination with the increased awareness and knowledge of risk factors among both clinicians and patients, have enabled an early and accurate diagnosis of ectopic pregnancy. As a consequence, the clinical presentation of ectopic pregnancy has changed from a life threatening disease to a more benign condition. This in turn has resulted in major changes in the options available for therapeutic management. Many treatment options are now available to the clinician in the treatment of tubal pregnancy: surgical treatment, which can be performed radically or conservatively, either laparoscopically or by an open surgical procedure; medical treatment, with a variety of drugs, that can be administered systemically and/or locally by different routes (transvaginally under sonographic guidance or under laparoscopic guidance); expectant management. The choice of a treatment modality should be based on short-term outcome measures (primary treatment success and reinterventions for clinical symptoms or persistent trophoblast) and on long-term outcome measures (tubal patency and future fertility). OBJECTIVES In the treatment of tubal pregnancy various types of treatments are available: surgical treatment, medical treatment and expectant management. In this review the effects of various treatments are summarized in terms of treatment success, need for reinterventions, tubal patency and future fertility. SEARCH STRATEGY The Cochrane Menstrual Disorders and Subfertility Group trials register and MEDLINE were searched. SELECTION CRITERIA Randomized controlled trials comparing treatments in women with ectopic pregnancy. DATA COLLECTION AND ANALYSIS Trial quality was assessed and data extracted independently by two reviewers. Differences were resolved by discussion with all reviewers. MAIN RESULTS Laparoscopic conservative surgery is significantly less successful than the open surgical approach in the elimination of tubal pregnancy due to a higher persistent trophoblast rate of laparoscopic surgery. Long term follow-up shows similar tubal patency rates, whereas the number of subsequent intrauterine pregnancies is comparable, and the number of repeat ectopic pregnancies lower, although these differences are not statistically significant. The laparoscopic approach is less costly as a result of significantly less blood loss and analgesic requirement, and a shorter duration of operation time, hospital stay, and convalescence time. Compared to laparoscopic conservative surgery (salpingostomy) local methotrexate is not a treatment option. Injection of this drug, both under laparoscopic guidance and under ultrasound guidance, is significantly less successful in the elimination of tubal pregnancy. Systemic methotrexate in a single dose intramuscular regimen is not effective enough in eliminating the tubal pregnancy compared to laparoscopic salpingostomy. This as a result of inadequately declining serum hCG concentrations after one single dose of methotrexate necessitating additional methotrexate injections or surgical interventions. If methotrexate primarily given in a multiple dose intramuscular regimen is compared with laparoscopic salpingostomy no large differences are found in medical outcomes, both short term and long term. However, this treatment regimen is associated with a greater impairment of health related quality of life and is more expensive, due to surgical interventions for clinical signs of tubal rupture, generating additional direct costs due to prolonged hospital stay. Furthermore, indirect costs due to productivity loss are higher. Only in patients with low initial serum hCG concentrations systemic methotrexate leads to costs savings compared to laparoscopic salpingostomy.
Collapse
Affiliation(s)
- P J Hajenius
- Department of Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, PO Box 22700, Amsterdam, The Netherlands, 1100 DE.
| | | | | | | | | |
Collapse
|
32
|
|
33
|
Hajenius PJ, Van der Veen F, Ankum WM. Cervical pregnancy-a conservative stepwise approach. Hum Reprod 1999; 14:2677-8. [PMID: 10528007 DOI: 10.1093/humrep/14.10.2677-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Single-dose methotrexate Combined with Chinese medicinal herbs treated unruptured and ruptured ectopic pregnancy. Chin J Integr Med 1999. [DOI: 10.1007/bf02934188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Natofsky JG, Lense J, Mayer JC, Yeko TR. Ultrasound-guided injection of ectopic pregnancy. Clin Obstet Gynecol 1999; 42:39-47; quiz 55-6. [PMID: 10073298 DOI: 10.1097/00003081-199903000-00008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Preliminary studies have demonstrated that salpingocentesis is a safe and effective treatment for unruptured ectopic pregnancies that are visible by transvaginal ultrasound. So far, experience with this technique has been confined to only a few centers around the world. The most promising results of these studies has been the virtual absence of side effects associated with local injection of either methotrexate or hyperosmolar glucose. Large prospective trials comparing efficacy, safety, and overall cost of salpingocentesis against systemic methotrexate will be necessary to better define the role of salpingocentesis in the management of ectopic pregnancy. Patient recruitment for this type of clinical trial would be feasible and acceptable to patients because both treatment arms would avoid surgery.
Collapse
Affiliation(s)
- J G Natofsky
- Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa 33606, USA
| | | | | | | |
Collapse
|
36
|
Abstract
In selected patients who are hemodynamically stable with an unruptured tubal pregnancy, systemic methotrexate has success rates comparable to laparoscopic salpingostomy. Larger randomized studies are necessary to adequately assess subsequent fertility. Local injection of methotrexate or other agents requires a sonographically visible ectopic as well as technical skills, and has less consistent success rates than that of systemic MTX therapy.
Collapse
|
37
|
Abstract
Ectopic pregnancy accounts for 2 percent of all pregnancies in the United States, and contributes substantially to maternal morbidity and mortality. Risk factors for the development of ectopic pregnancy are described, but less than 50 percent of women with ectopic pregnancy actually give a history of such risk factors. The initial history and physical examination of patients who eventually are found to have ectopic pregnancy can be misleading, resulting in early misdiagnosis. Failure to diagnose ectopic pregnancy before tubal rupture limits treatment options. However, with a high index of suspicion, and a combination of biochemical and ultrasound parameters, early diagnosis of ectopic pregnancy can be achieved, permitting medical or conservative surgical treatment options. Future reproductive potential after treatment of ectopic pregnancy is limited, with only approximately one third of affected women ever subsequently delivering a live-born infant. Future fertility is more dependent on the condition of the contralateral fallopian tube than on the specific type of therapy used to treat the affected tube. There is no consensus on which treatment is most effective, minimizing the risk of persistent ectopic pregnancy, while providing the optimum future fertility potential.
Collapse
Affiliation(s)
- D L Fylstra
- Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA
| |
Collapse
|
38
|
Creinin MD, Krohn MA. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. Am J Obstet Gynecol 1997; 177:1444-9. [PMID: 9423749 DOI: 10.1016/s0002-9378(97)70089-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVE Our goal was to evaluate the pharmacokinetics and safety of methotrexate in doses of 50 mg/m2 and 60 mg/m2 in regimens for early abortion. STUDY DESIGN A randomized controlled trial was performed in women requesting an abortion at < or = 49 days' gestation. Twenty women were treated with intramuscular methotrexate 50 mg/m2 (group 1) or 60 mg/m2 (group 2). Methotrexate levels were determined serially for the first 24 hours, then every 24 hours for 7 days. On the seventh day misoprostol 800 microg was administered vaginally. The misoprostol dose was repeated 24 hours later if abortion did not occur. RESULTS Complete abortion occurred in 9 of 10 (90%, 95% confidence interval 56% to 100%) patients in group 1 and all 10 (100%, 95% confidence interval 69% to 100%; p = 0.99) in group 2. Methotrexate levels peaked within 1 to 2 hours and were nondetectable within 48 hours in all patients in group 1 and 72 hours in group 2. Both the maximum concentration of methotrexate and the area under the curve were significantly greater for group 2. Methotrexate clearance rates were 7.89 +/- 1.98 L/hr and 5.55 +/- 0.83 L/hr (p = 0.003), respectively. CONCLUSIONS The serum levels of intramuscular methotrexate with 50 mg/m2 and 60 mg/m2 regimens indicate that these are safe treatment doses. Methotrexate 50 mg/m2 intramuscularly has the same clearance rates when administered during pregnancy as in a nonpregnant state, and maximum concentrations do not reach sustained toxic levels.
Collapse
Affiliation(s)
- M D Creinin
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pennsylvania, USA
| | | |
Collapse
|
39
|
Fernandez H. Methotrexate in tubal pregnancy. Lancet 1997; 350:1555; author reply 1555-6. [PMID: 9388433 DOI: 10.1016/s0140-6736(05)63993-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
40
|
UNDP/UNFPA/WHO/World Bank Special P. Methotrexate for the termination of early pregnancy: a toxicology review. REPRODUCTIVE HEALTH MATTERS 1997. [DOI: 10.1016/s0968-8080(97)90020-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
41
|
Abstract
OBJECTIVES To review the efficacy, safety, costs, and subsequent reproductive outcome of surgical and nonsurgical management of ectopic pregnancy (EP). DESIGN Pertinent studies were identified through computer Medline search. The rates of intrauterine pregnancy (IUP) and EP were calculated from the raw data in the original publications so that the denominator would be consistent. RESULT(S) The efficacy of laparoscopic treatment of EP is similar to that by laparotomy. The rate of persistent EP after conservative surgery ranges from 3% to 20%. Based on a review of 1,514 patients attempting to conceive after linear salpingostomy, the IUP and recurrent EP rates were 61.4% and 15.4%, respectively, among patients who had laparotomy, and 61% and 15.5%, respectively, among patients who had laparoscopic procedure. Of 3,584 patients who had partial or total salpingectomy, the subsequent IUP rate was 38.1% and the recurrent EP rate was 9.8%. Of 540 patients treated with a single-dose methotrexate, 84% did not require further treatment and, among 215 patients who attempted to conceive, 54% had subsequent IUP and 8% had recurrent EP. The success rate of expectant management was 69.2% in 347 patients reviewed. CONCLUSION(S) There is no difference in the reproductive outcome after treatment of EP by laparotomy and by laparoscopy. Salpingostomy is associated with higher subsequent IUP and recurrent EP rates compared with salpingectomy. Methotrexate is a viable alternative to laparoscopic salpingostomy for a selected group of patients.
Collapse
Affiliation(s)
- M Yao
- Royal Victoria Hospital, Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
| | | |
Collapse
|
42
|
Benifla JL, Fernandez H, Sebban E, Darai E, Frydman R, Madelenat P. Alternative to surgery of treatment of unruptured interstitial pregnancy: 15 cases of medical treatment. Eur J Obstet Gynecol Reprod Biol 1996; 70:151-6. [PMID: 9119095 DOI: 10.1016/s0301-2115(95)02589-8] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE To evaluate medical treatment of interstitial pregnancy. METHODS This series was a retrospective study of medical treatment of interstitial pregnancies which was managed in two French Departments of Obstetrics and Gynecology (Bichat public Hospital. Paris and A. Béclère public Hospital, Clamart, France). Fifteen patients with clear evidence of an unruptured interstitial pregnancy were treated by injection of methotrexate (MTX) or potassium chloride (KCL) without surgery since January 1988. The diagnosis was established either by sonography and laparoscopic confirmation in eight cases or by only transvaginal ultrasound in seven cases. Three out of 15 cases in this series, had a heterotopic pregnancy who were treated by transvaginal ultrasound-guided injection of KCL. Others received systemic MTX injection in four cases, and local MTX injection in eight cases under either laparoscopy or transvaginal ultrasound guidance. Four different protocols of MTX (Ledertrexate) administration was performed in this series with time: at the beginning of our experience, MTX1 protocol, 15 mg i.m. daily for 5 days was used; and after MTX2 protocol, 1 mg/kg body weight i.m. daily for 4 days; MTX3 protocol, 1 mg/kg body weight intratubal associated with 1 mg/kg body weight i.m. daily for 3 days; and now MTX4 protocol, only intratubal 1 mg/kg body weight is especially used. The success was defined as declining serum human chorionic gonadotropin (hCG) to undetectable levels, and no further surgical management was required. Outcome of subsequent fertility was also evaluated. RESULTS Complete resolution was obtained in 13 (86.6%) out of 15 interstitial pregnancies. Two out of 15 patients, with medical treatment's failure required secondary surgery. No severe side effects of medical treatment were observed. Follow-up hysterosalpingography was performed in 12 patients showing 91.7% tubal patency on the side of interstitial pregnancy. Outcome of intra-uterine pregnancy of the three patients who had heterotopic gestation, was two miscarriages and one delivery at term. Out of the other 12 patients in this series, nine became pregnant within 1 year: eight pregnancies at term, and one induced abortion. At present, among the last three patients, two have no desire to conceive. CONCLUSION Our results suggest that unruptured interstitial pregnancies now can be managed with local MTX administration of 1 mg/kg body weight under transvaginal ultrasound or under laparoscopy procedure. This approach is particularly attractive in these patients, where the only alternative to therapy is laparotomy with cornual resection.
Collapse
Affiliation(s)
- J L Benifla
- Department of Obstetrics and Gynecology, Hôpital Bichat, Paris, France
| | | | | | | | | | | |
Collapse
|
43
|
Floridon C, Nielsen O, Byrjalsen C, Hølund B, Kerndrup G, Thomsen SG, Andersen JA. Ectopic pregnancy: histopathology and assessment of cell proliferation with and without methotrexate treatment**Supported by Wyeth/Lederle, Copenhagen, Denmark.††Presented in part at the Fifth Conference of Endocrinology and Metabolism in Human Reproduction, Academic Unit of Obstetrics and Gynaecology, London, United Kingdom, March 27 to 29, 1995. Fertil Steril 1996. [DOI: 10.1016/s0015-0282(16)58205-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
|